Primary Job Title President , CEO & Chairman of the Board Primary Organization Collegium Pharmaceutical
Location Hingham, Massachusetts, United States Regions Greater Boston Area, East Coast, New England Gender Male
LinkedIn View on LinkedIn
Michael Heffernan has 25 years of experience in the pharmaceutical and related healthcare industries. He is currently Co-Founder, President, CEO of Collegium Pharmaceutical. Collegium is specialty pharmaceutical company focused on the development of pharmaceutical products for the treatment of chronic pain.
He was also previously the founder,
President and CEO of Onset Therapeutics, a dermatology focused company that develops and commercializes products for the treatment of skin related illnesses and was responsible for the spin-off of this business to create PreCision Dermatology.
Michael held prior positions as Co-Founder, President and CEO of Clinical Studies Ltd., a pharmaceutical contract research organization that he successfully sold.
He also served as President and CEO of PhyMatrix, a public $400 million integrated healthcare services company where he was hired to restructure the company.
Michael started his career at Eli Lilly and Company and served in numerous sales and marketing roles. He has also been a member of the Board of Directors, Advisor and Angel Investor in a number of healthcare companies.
He is currently a member of the Board of Directors of TyRx, a venture backed medical device company, Cornerstone Therapeutics (NASDAQ:CRTX), a specialty pharmaceutical company and PreCision Dermatology.
Michael earned his B.S. Degree in Pharmacy from the University of Connecticut and is a Registered Pharmacist.
